Squarepoint
XFOR icon

Squarepoint’s X4 Pharmaceuticals XFOR Stock Holding History

Squarepoint’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$242K Buy
83,488
+16,410
+24% +$63.6K ﹤0.01% 3949
2026
Q2 		$313K Buy
+67,078
New +$275K ﹤0.01% 3774
2026
Q1 		– Sell
-12,518
Closed -$50.1K – 5081
2025
Q4 		$50.1K Buy
+12,518
New +$45.5K ﹤0.01% 4131
2025
Q3 		– Sell
-38,982
Closed -$74.1K – 5090
2025
Q2 		$74.1K Buy
+38,982
New +$160K ﹤0.01% 4235
2024
Q1 		– Sell
-2,159
Closed -$54.3K – 4688
2023
Q4 		$54.3K Buy
+2,159
New +$52.5K ﹤0.01% 3838
2021
Q3 		– Sell
-688
Closed -$134K – 3490
2021
Q2 		$134K Sell
688
-15
-2% -$3.77K ﹤0.01% 2959
2021
Q1 		$181K Buy
703
+131
+23% +$34.4K ﹤0.01% 2736
2020
Q4 		$110K Buy
572
+171
+43% +$33.6K ﹤0.01% 2704
2020
Q3 		$81K Sell
401
-309
-44% -$74.1K ﹤0.01% 2319
2020
Q2 		$199K Buy
+710
New +$194K ﹤0.01% 1825
2020
Q1 		– Sell
-456
Closed -$146K – 2603
2019
Q4 		$146K Buy
+456
New +$164K ﹤0.01% 2289
2019
Q1 		– Sell
-193
Closed -$81K – 2476
2018
Q4 		$81K Buy
193
+104
+117% +$39.7K ﹤0.01% 1817
2018
Q3 		$26K Buy
+89
New +$37.7K ﹤0.01% 1938

Other funds holding XFOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Squarepoint's XFOR Position: Q3 2026 in Review

Squarepoint increased its X4 Pharmaceuticals (XFOR) stake by 24% in Q3 2026, buying an estimated $63.6K and bringing the position to 83,488 shares worth $242K. The position accounts for ﹤0.01% of the portfolio, ranked #3949.

Squarepoint first reported a position in XFOR in Q3 2018 and has held it in 13 quarters since. The position peaked at $313K in Q2 2026. 27 funds tracked by Wall St. Rank hold XFOR as of Q3 2026.

  • Squarepoint held 83,488 shares of X4 Pharmaceuticals worth $242K as of Q3 2026.
  • Squarepoint bought 16,410 X4 Pharmaceuticals shares in Q3 2026, an estimated $63.6K.
  • X4 Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #3949 holding.
  • Squarepoint first reported a position in X4 Pharmaceuticals in Q3 2018 and has held it in 13 quarters since.
  • Squarepoint's X4 Pharmaceuticals position peaked at $313K in Q2 2026.
  • 27 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.